Acetal Ester Linker for Aptamer-Triptolide Conjugate
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The existing aptamer-triptolide conjugates have a linker with low acid sensitivity, resulting in insufficient targeted release of triptolide in tumor cells, leading to a weak inhibitory effect on cancer cells.
Innovation Solution
A novel acid-sensitive conjugate of an aptamer and triptolide is developed, utilizing an acetal ester moiety as the linker between triptolide and the aptamer, which cleaves in the acidic lysosomal environment of tumor cells, allowing for precise release of triptolide.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If a vinyl ether moiety is used as the acidic linker to connect triptolide and an aptamer, then the conjugate can be formed, but the acid sensitivity is low and the linker is not easily ruptured in the in vivo cancer cell environment, resulting in insufficient targeted release of triptolide
Solution Approach 1:
The patent changes the chemical structure parameter of the linker from vinyl ether moiety to acetal ester moiety. This structural parameter change fundamentally alters the pH sensitivity characteristics, enabling the linker to be stable at physiological pH (7.4) while being readily cleaved in the acidic tumor microenvironment (pH 5.0-6.5), thus simultaneously achieving both stability and cleavability
Solution Approach 2:
The patent creates a composite conjugate structure comprising triptolide, aptamer, and acetal ester linker. This composite design integrates the targeting function of the aptamer with the acid-sensitive release function of the acetal ester linker, achieving both stable circulation and targeted release at the tumor site
2Object-affected harmful factors
If triptolide is used directly, then strong anti-tumor activity is achieved, but toxic side actions are significant and water solubility is poor
Solution Approach 1:
The patent segments the drug delivery system into three functional components: the cytotoxic agent (triptolide), the targeting molecule (aptamer), and the environment-responsive linker (acetal ester). This segmentation allows triptolide to be delivered specifically to tumor cells via the aptamer-targeted approach, maintaining its anti-tumor activity while reducing exposure to normal cells and thereby minimizing toxic side effects
Solution Approach 2:
The acetal ester linker serves as an intermediary that connects triptolide to the aptamer. This intermediary is stable in circulation, protecting triptolide from premature release, but cleaves in the acidic tumor microenvironment to release active triptolide at the target site, thus maintaining efficacy while reducing systemic toxicity
3Productivity
If the linker is made more acid-sensitive to improve targeted release, then the release efficiency increases, but the stability of the conjugate in circulation may be compromised
Solution Approach 1:
The patent optimizes the chemical structure parameters of the acetal ester linker to achieve the desired balance. By carefully designing the acetal ester structure (with specific substituents R1 and R2), the linker exhibits pH-dependent stability: remaining intact at physiological pH (7.4) for stable circulation, while being rapidly cleaved in the acidic tumor microenvironment (pH 5.0-6.5) for efficient drug release
Solution Approach 2:
The patent introduces dynamic pH-responsiveness into the linker system. The acetal ester linker dynamically adapts its stability based on the local pH environment: maintaining a stable conjugate structure in the bloodstream (pH 7.4) and transitioning to rapid cleavage in the acidic tumor microenvironment (pH 5.0-6.5), thus achieving both circulation stability and release efficiency
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The acid-sensitive linker ensures effective targeting and release of triptolide within tumor cells, enhancing anti-tumor effects while minimizing toxicity to normal cells, with improved stability and responsiveness to the tumor microenvironment.
Implementation Method 1
the linker comprises an acetal ester moiety formed at the 14-OH position... which cleaves in the acidic lysosomal environment of tumor cells
Data Source
Figure 1~2
Figure 3~4
Figure 5~6
AI summary
The present invention relates to the fields of medicine and chemical industry, and in particular to a conjugate of an aptamer and triptolide (TPL), which is sensitive to weak-acid tumor microenvironment (TME). The conjugate is linked by a linker comprising an acetal ester moiety between 14-OH of triptolide and the aptamer, which is an acid-sensitive moiety with a cleavage condition of (pH = 3.5-6.5) and lower pH sensitivity, thereby making it easier to break in the tumor microenvironment. Based on the characteristic of the aptamer targeting high-expression proteins on tumor cell membranes, this conjugate delivers triptolide to tumor cells, which enters lysosomes by mediating endocytosis; based on the characteristics of lysosomal acidic environment, intact triptolide is released in lysosomal acidic environment due to the rupture of the acetal ester moieties, thereby producing target killing effects on tumor cells. This overcomes the following shortcomings, that is, the acid sensitivity of the linker for the aptamer-triptolide conjugate in the prior art is low, which is not easily broken in the in vivo environment of cancer cells, resulting in insufficient targeted release of triptolide, and thus the inhibitory effects on cancer cells are not significant.